EQL Daytime Cold/Flu Relief and Lomitapide

In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.

Lomitapide may cause liver problems, and using it with other medications that can also affect the liver such as acetaminophen may increase that risk. You should avoid or limit the use of alcohol to no more than one drink per day while being treated with these medications. Call your doctor immediately if you have fever, chills, joint pain or swelling, unusual bleeding or bruising, skin rash, itching, loss of appetite, fatigue, nausea, vomiting, abdominal pain, dark urine, pale stools, and/or yellowing of the skin or eyes, as these may be signs and symptoms of liver damage. Talk to your doctor or pharmacist if you have any questions or concerns. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.

MONITOR CLOSELY: Coadministration of lomitapide with other agents known to induce hepatotoxicity may potentiate the risk of liver injury. Lomitapide can cause elevations in serum transaminases and hepatic steatosis. In a premarketing clinical trial, 34% (10/29) of patients treated with lomitapide had at least one elevation in alanine aminotransferase (ALT) or aspartate aminotransferase (AST) 3 times the upper limit of normal (ULN) or greater, and 14% (4/29) had at least one elevation in ALT or AST 5 times ULN or greater. There were no concomitant clinically meaningful elevations of total bilirubin, international normalized ratio (INR), or alkaline phosphatase. Lomitapide also increases hepatic fat, with or without concomitant increases in transaminases. In the same study, the median absolute increase in hepatic fat was 6% after both 26 and 78 weeks of treatment, from 1% at baseline, measured by magnetic resonance spectroscopy. Hepatic steatosis associated with lomitapide may be a risk factor for progressive liver disease, including steatohepatitis and cirrhosis. Clinical data suggest that hepatic fat accumulation is reversible after stopping treatment with lomitapide, although the long-term consequences are unknown.

MANAGEMENT: Caution is advised if lomitapide is used with other potentially hepatotoxic agents (e.g., acetaminophen; alcohol; amiodarone; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; methotrexate; nonsteroidal anti-inflammatory agents; nucleoside reverse transcriptase inhibitors; proteasome inhibitors; retinoids; tamoxifen; tetracyclines; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; other lipid-lowering medications such as fenofibrate, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice). Patients treated with lomitapide should have serum ALT, AST, alkaline phosphatase, and total bilirubin measured prior to initiation of treatment and regularly during treatment in accordance with the product labeling, and the dosing adjusted or interrupted as necessary. Since alcohol may increase levels of hepatic fat and induce or exacerbate liver injury, the manufacturer recommends that patients taking lomitapide not consume more than one alcoholic drink per day. Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice.

EQL Daytime Cold/Flu Relief

Generic Name: acetaminophen / dextromethorphan / pseudoephedrine

Brand name: Alka-Seltzer Plus Flu/Body, DayQuil Multi-Symptom Cold/Flu, EQ Daytime Cold/Flu Relief, EQ Flu Relief, EQL Daytime Cold/Flu Relief, Tylenol Flu Maximum Strength, Sudafed Severe Cold, Tylenol Cold and Flu No Drowsiness Powder, Tylenol Cold No Drowsiness, Theraflu No Drowsiness Maximum Strength, Triaminic Sore Throat Formula, Contac Severe Cold and Flu Non Drowsy, Tylenol Cough Liquid with Decongestant, DayQuil, Day Time Multi Symptom, Triaminic Cold and Fever Formula, Sudafed Decongestant Cold and Cough, Tylenol Cold Severe Congestion, Tylenol Infants Cold Plus Cough, Robitussin Honey Flu, Extra Strength Tylenol Flu Daytime, Non-Drowsy Super Strength Contac Complete, Contact Cold and Sore Throat, Tylenol Cold & Flu Severe Day Time, Vicks Dayquil Daytime Cold/Flu, Triaminic Cough & Sore Throat, Theraflu Severe Cold & Congestion Non-Drowsy, Triaminic Softchews Cough & Sore Throat, Day Relief Cold and Flu, Tylenol Cold & Flu Daytime, Tylenol Cold Non-Drowsy Caplets, Tylenol Cold Non-Drowsy Gelcaps, Daytime Cold and Flu Relief, Daytime Non-Drowsy, Theraflu Daytime Severe Cold, Severe Cold Multi-Sympton

Synonyms: n.a.

What is EQL Daytime Cold/Flu Relief?

Lomitapide

Generic Name: lomitapide

Brand name: Juxtapid

Synonyms: n.a.

What is Lomitapide?